Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
| ▸ | HTR2B | P41595 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.42 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | MMP8 | P22894 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | CASR | P41180 | 2/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | GHSR | Q92847 | 1/20 | 0.38 |
| ▸ | TACR1 | P25103 | 2/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | MME | P08473 | 1/20 | 0.38 |
| ▸ | ACE | P12821 | 1/20 | 0.38 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6575417 | 1.00 | HTR2A (0.45) | HTR2AHTR2CHTR2BSIGMAR1MMP9 | |
| SCHEMBL6577672 | 0.85 | OPRK1 (0.43) | HTR2ASIGMAR1CYP1A2CYP2A6 | |
| SCHEMBL6577676 | 0.85 | OPRK1 (0.43) | HTR2ASIGMAR1CYP1A2CYP2A6 | |
| SCHEMBL6579394 | 0.78 | HTR2A (0.53) | HTR2AHTR2CHTR2BSIGMAR1CYP1A2 | |
| SCHEMBL6579390 | 0.78 | HTR2A (0.53) | HTR2AHTR2CHTR2BSIGMAR1CYP1A2 | |
| SCHEMBL6580073 | 0.73 | TRPA1 (0.41) | HTR2ACYP1A2 | |
| SCHEMBL6580062 | 0.73 | TRPA1 (0.41) | HTR2ACYP1A2 | |
| SCHEMBL6577648 | 0.69 | TRPA1 (0.46) | HTR2ACYP1A2 | |
| SCHEMBL6577654 | 0.69 | TRPA1 (0.46) | HTR2ACYP1A2 | |
| SCHEMBL809100 | 0.68 | SLC6A2 (0.44) | HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040236118-A1 | Pyrrolidine derivatives and method of synthesizing these | EIZAI CO., LTD (JP) | 2004-11-25 | — | — | US | disclosed |
| EP-1413574-A1 | PYRROLIDINE DERIVATIVES AND METHOD OF SYNTHESIZING THESE | Eizai Co., Ltd. (JP) | 2004-04-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040236118-A1 | Pyrrolidine derivatives and method of synthesizing these | ADH1C, ADH5, ADH1A | HTR2A 2041/4885HTR2C 1428/4885HTR2B 2419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.